(Q39467165)

12 September 2017

A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance (English)

1 reference

non-small-cell lung carcinoma

12 September 2017

1 reference

Erika Taube

1

1 reference

12 September 2017

Elina Jokinen

series ordinal

2

1 reference

12 September 2017

Peppi Koivunen

series ordinal

3

1 reference

12 September 2017

Jussi P Koivunen

series ordinal

4

1 reference

12 September 2017

language of work or name

English

0 references

publication date

8 November 2011

1 reference

International Journal of Cancer

12 September 2017

1 reference

12 September 2017

131

1 reference

12 September 2017

970-979

1 reference

12 September 2017

4

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

12 September 2017

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

21 January 2018

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

21 January 2018

1 reference

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

21 January 2018

1 reference

Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells

21 January 2018

1 reference

Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells

21 January 2018

1 reference

EGFR signals to mTOR through PKC and independently of Akt in glioma

21 January 2018

1 reference

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy

21 January 2018

1 reference

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26461

1 reference

12 September 2017

1 reference